RPG Life Sciences · NSE: RPGLIFE · BSE: 532983
Q1 FY21 results · Apr–Jun 2020
RPG Life Sciences reported revenue from operations of ₹91.65 crore (down 2.5% from Q1 FY20) and net profit of ₹9.06 crore (up 8.5% from Q1 FY20) for Q1 FY21 (Apr–Jun 2020), on a standalone basis.
| Item | Q1 FY21 | Q1 FY20 | YoY | Q4 FY20 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 91.65 | 94.04 | −2.5% | 88.67 | +3.4% |
| Other income | 0.45 | 0.16 | +181.2% | 0.38 | +18.4% |
| Total income | 92.10 | 94.20 | −2.2% | 89.05 | +3.4% |
| Profit before tax | 12.83 | 10.86 | +18.1% | 3.14 | +308.6% |
| Net profit for the period | 9.06 | 8.35 | +8.5% | 2.98 | +204.0% |
| EPS, basic (₹) | 5.48 | 5.05 | +8.5% | 1.80 | +204.4% |
| Net margin (%) | 9.9 | 8.9 | 3.4 |
Standalone
- Filed with BSE
- 06 Aug 2020, 16:04 IST
- Board meeting
- 31 Jul 2020
- Period
- 01 Apr 2020 to 30 Jun 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE